Effect of phylloquinone supplementation on biochemical markers of vitamin K status and bone turnover in postmenopausal women

Susanne Bügel; Anne Dorthe Sørensen; Ole Hels; M Kristensen; Cees Vermeer; Jette Jakobsen; Albert Flynn; Christian Mølgaard; Kevin D Cashman

doi:10.1017/S000711450715460X

Effect of phylloquinone supplementation on biochemical markers of vitamin K status and bone turnover in postmenopausal women

Susanne Bügel^*, Anne Dorthe Sørensen, Ole Hels, M Kristensen, Cees Vermeer, Jette Jakobsen, Albert Flynn, Christian Mølgaard, Kevin D Cashman

^*Corresponding author for this work

24 Citations (Scopus)

Abstract

While current intakes of phylloquinone (vitamin K1) in many populations are believed to be sufficient to maintain normal blood coagulation, these may be insufficient to cover the requirements for optimal bone metabolism. Therefore, the objective of the present study was to investigate the effect of increasing phylloquinone intakes above the usual dietary intake for 6 weeks on biochemical markers of vitamin K status and bone turnover in postmenopausal women. Thirty-one postmenopausal women completed this 3 × 6-week randomised cross-over study, in which volunteers were supplemented with 0 (placebo), 200, and 500 μg phylloquinone/d. In addition, the volunteers were given 10 μg vitamin D3/d throughout the study period. With increasing phylloquinone intake, the concentration of serum g-carboxylated and under-g-carboxylated osteocalcin was significantly increased and decreased, respectively, in a dose-dependent manner (P<0·001). Mean serum phylloquinone concentration was significantly (P<0·001) higher with daily supplementation with 500 μg phylloquinone/d compared with that during either of the placebo or 200 μg phylloquinone/d supplementation periods, which did not differ (P=0·15). Serum total osteocalcin was significantly (P<0·001) increased in response to daily supplementaiont with 500 (but not 200) μg phylloquinone compared with placebo. Serum bone-specific alkaline phosphatase as well as the urinary markers of bone resorption (N-telopeptide cross-links of collagen, pyridinoline and deoxypyridinoline) and urinary g-carboxyglutamate were unaffected by phylloquinone supplementation. In conclusion, while daily supplementation with 200 and 500 μg phylloquinone/d for 6 weeks increased vitamin K status in postmenopausal women, it had no effect on bone turnover.

Original language	English
Journal	British Journal of Nutrition
Volume	97
Issue number	2
Pages (from-to)	373-380
Number of pages	8
ISSN	0007-1145
DOIs	https://doi.org/10.1017/S000711450715460X
Publication status	Published - 2007

Keywords

Bone biochemical markers
Osteocalcin
Phylloquinone supplementation
Postmenopausal women
Vitamin K status

Access to Document

10.1017/S000711450715460X

Cite this

@article{c9a919c83e8f4af08fcea7fcd38d8f79,

title = "Effect of phylloquinone supplementation on biochemical markers of vitamin K status and bone turnover in postmenopausal women",

abstract = "While current intakes of phylloquinone (vitamin K1) in many populations are believed to be sufficient to maintain normal blood coagulation, these may be insufficient to cover the requirements for optimal bone metabolism. Therefore, the objective of the present study was to investigate the effect of increasing phylloquinone intakes above the usual dietary intake for 6 weeks on biochemical markers of vitamin K status and bone turnover in postmenopausal women. Thirty-one postmenopausal women completed this 3 × 6-week randomised cross-over study, in which volunteers were supplemented with 0 (placebo), 200, and 500 μg phylloquinone/d. In addition, the volunteers were given 10 μg vitamin D3/d throughout the study period. With increasing phylloquinone intake, the concentration of serum g-carboxylated and under-g-carboxylated osteocalcin was significantly increased and decreased, respectively, in a dose-dependent manner (P<0·001). Mean serum phylloquinone concentration was significantly (P<0·001) higher with daily supplementation with 500 μg phylloquinone/d compared with that during either of the placebo or 200 μg phylloquinone/d supplementation periods, which did not differ (P=0·15). Serum total osteocalcin was significantly (P<0·001) increased in response to daily supplementaiont with 500 (but not 200) μg phylloquinone compared with placebo. Serum bone-specific alkaline phosphatase as well as the urinary markers of bone resorption (N-telopeptide cross-links of collagen, pyridinoline and deoxypyridinoline) and urinary g-carboxyglutamate were unaffected by phylloquinone supplementation. In conclusion, while daily supplementation with 200 and 500 μg phylloquinone/d for 6 weeks increased vitamin K status in postmenopausal women, it had no effect on bone turnover.",

keywords = "Bone biochemical markers, Osteocalcin, Phylloquinone supplementation, Postmenopausal women, Vitamin K status",

author = "Susanne B{\"u}gel and S{\o}rensen, {Anne Dorthe} and Ole Hels and M Kristensen and Cees Vermeer and Jette Jakobsen and Albert Flynn and Christian M{\o}lgaard and Cashman, {Kevin D}",

year = "2007",

doi = "10.1017/S000711450715460X",

language = "English",

volume = "97",

pages = "373--380",

journal = "British Journal of Nutrition",

issn = "0007-1145",

publisher = "Cambridge University Press",

number = "2",

}

TY - JOUR

T1 - Effect of phylloquinone supplementation on biochemical markers of vitamin K status and bone turnover in postmenopausal women

AU - Bügel, Susanne

AU - Sørensen, Anne Dorthe

AU - Hels, Ole

AU - Kristensen, M

AU - Vermeer, Cees

AU - Jakobsen, Jette

AU - Flynn, Albert

AU - Mølgaard, Christian

AU - Cashman, Kevin D

PY - 2007

Y1 - 2007

N2 - While current intakes of phylloquinone (vitamin K1) in many populations are believed to be sufficient to maintain normal blood coagulation, these may be insufficient to cover the requirements for optimal bone metabolism. Therefore, the objective of the present study was to investigate the effect of increasing phylloquinone intakes above the usual dietary intake for 6 weeks on biochemical markers of vitamin K status and bone turnover in postmenopausal women. Thirty-one postmenopausal women completed this 3 × 6-week randomised cross-over study, in which volunteers were supplemented with 0 (placebo), 200, and 500 μg phylloquinone/d. In addition, the volunteers were given 10 μg vitamin D3/d throughout the study period. With increasing phylloquinone intake, the concentration of serum g-carboxylated and under-g-carboxylated osteocalcin was significantly increased and decreased, respectively, in a dose-dependent manner (P<0·001). Mean serum phylloquinone concentration was significantly (P<0·001) higher with daily supplementation with 500 μg phylloquinone/d compared with that during either of the placebo or 200 μg phylloquinone/d supplementation periods, which did not differ (P=0·15). Serum total osteocalcin was significantly (P<0·001) increased in response to daily supplementaiont with 500 (but not 200) μg phylloquinone compared with placebo. Serum bone-specific alkaline phosphatase as well as the urinary markers of bone resorption (N-telopeptide cross-links of collagen, pyridinoline and deoxypyridinoline) and urinary g-carboxyglutamate were unaffected by phylloquinone supplementation. In conclusion, while daily supplementation with 200 and 500 μg phylloquinone/d for 6 weeks increased vitamin K status in postmenopausal women, it had no effect on bone turnover.

AB - While current intakes of phylloquinone (vitamin K1) in many populations are believed to be sufficient to maintain normal blood coagulation, these may be insufficient to cover the requirements for optimal bone metabolism. Therefore, the objective of the present study was to investigate the effect of increasing phylloquinone intakes above the usual dietary intake for 6 weeks on biochemical markers of vitamin K status and bone turnover in postmenopausal women. Thirty-one postmenopausal women completed this 3 × 6-week randomised cross-over study, in which volunteers were supplemented with 0 (placebo), 200, and 500 μg phylloquinone/d. In addition, the volunteers were given 10 μg vitamin D3/d throughout the study period. With increasing phylloquinone intake, the concentration of serum g-carboxylated and under-g-carboxylated osteocalcin was significantly increased and decreased, respectively, in a dose-dependent manner (P<0·001). Mean serum phylloquinone concentration was significantly (P<0·001) higher with daily supplementation with 500 μg phylloquinone/d compared with that during either of the placebo or 200 μg phylloquinone/d supplementation periods, which did not differ (P=0·15). Serum total osteocalcin was significantly (P<0·001) increased in response to daily supplementaiont with 500 (but not 200) μg phylloquinone compared with placebo. Serum bone-specific alkaline phosphatase as well as the urinary markers of bone resorption (N-telopeptide cross-links of collagen, pyridinoline and deoxypyridinoline) and urinary g-carboxyglutamate were unaffected by phylloquinone supplementation. In conclusion, while daily supplementation with 200 and 500 μg phylloquinone/d for 6 weeks increased vitamin K status in postmenopausal women, it had no effect on bone turnover.

KW - Bone biochemical markers

KW - Osteocalcin

KW - Phylloquinone supplementation

KW - Postmenopausal women

KW - Vitamin K status

U2 - 10.1017/S000711450715460X

DO - 10.1017/S000711450715460X

M3 - Journal article

C2 - 17298708

AN - SCOPUS:34247565048

SN - 0007-1145

VL - 97

SP - 373

EP - 380

JO - British Journal of Nutrition

JF - British Journal of Nutrition

IS - 2

ER -

Effect of phylloquinone supplementation on biochemical markers of vitamin K status and bone turnover in postmenopausal women

Abstract

Keywords

Access to Document

Fingerprint

Cite this